- Home
- MGRM vs VNDA Comparison
MGRM vs VNDA Comparison
Compare MGRM & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRM
- VNDA
- Stock Information
- Founded
- MGRM 2016
- VNDA 2002
- Country
- MGRM United States
- VNDA United States
- Employees
- MGRM N/A
- VNDA N/A
- Industry
- MGRM Medical/Dental Instruments
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- MGRM Health Care
- VNDA Health Care
- Exchange
- MGRM Nasdaq
- VNDA Nasdaq
- Market Cap
- MGRM 232.0M
- VNDA 249.4M
- IPO Year
- MGRM N/A
- VNDA 2006
- Fundamental
- Price
- MGRM $5.77
- VNDA $4.52
- Analyst Decision
- MGRM Strong Buy
- VNDA Strong Buy
- Analyst Count
- MGRM 1
- VNDA 2
- Target Price
- MGRM $5.40
- VNDA $16.50
- AVG Volume (30 Days)
- MGRM 98.1K
- VNDA 358.8K
- Earning Date
- MGRM 11-13-2025
- VNDA 11-05-2025
- Dividend Yield
- MGRM N/A
- VNDA N/A
- EPS Growth
- MGRM N/A
- VNDA N/A
- EPS
- MGRM N/A
- VNDA N/A
- Revenue
- MGRM N/A
- VNDA $203,467,000.00
- Revenue This Year
- MGRM N/A
- VNDA $15.45
- Revenue Next Year
- MGRM N/A
- VNDA $37.82
- P/E Ratio
- MGRM N/A
- VNDA N/A
- Revenue Growth
- MGRM N/A
- VNDA 11.78
- 52 Week Low
- MGRM $1.92
- VNDA $3.81
- 52 Week High
- MGRM $6.02
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- MGRM 59.95
- VNDA 49.27
- Support Level
- MGRM $5.67
- VNDA $4.36
- Resistance Level
- MGRM $5.87
- VNDA $4.64
- Average True Range (ATR)
- MGRM 0.14
- VNDA 0.15
- MACD
- MGRM -0.03
- VNDA -0.02
- Stochastic Oscillator
- MGRM 29.18
- VNDA 28.57
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.